Abstract
Chronic kidney disease (CKD) accelerates atherogenesis. Reactive aldehydes, including isoprostanes and isolevuglandins (IsoLG) are lipoxidation products carried by high density lipoprotein (HDL). These aldehydes promote cellular dysfunction underlying atherosclerosis and their levels are increased in CKD. We previously used aldehyde scavenger, eg., IsoLG scavenger - salicylamine (SAM) ) to lessen lipoxidation-induced cytotoxicity and now investigate the impact of this treatment on kidney-injury driven acceleration of atherosclerosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
